-
MLX 351 seeks your views on proposals for amendments to medicines legislation to allow dispensing opticians access to certain prescription only medicines (POMs).
-
We will be conducting a full review of the overall balance of risks and benefits of using long-acting beta2 agonists in asthma and chronic obstructive pulmonary disease (COPD).
-
When licensing a new medicine, the regulators focus on quality, safety, and how well it works. This page explains the process.
-
The more widely a medicine is prescribed, the more becomes known about its effects, and a change in use may be required. This page explains the process.
-
It is impossible to know everything about all the side effects and benefits of a medicine when it is first licensed. This page explains the process.
-
By law, before a medicine can be placed on the market, it must be given a marketing authorisation (product licence) by a medicines regulator. This page explains the process.
-
Once researchers know that a new compound could be useful as a potential treatment, and it has passed safety tests in pre-clinical research, it needs to be tested thoroughly in clinical trials. This page explains the process.
-
Before a promising compound can be safely tested on people, a great deal more detailed research must be done to answer vital questions about its chemical properties and ability to treat a particular disease or symptom. This page explains the process.
-
Finding suitable compounds which stand the best chance of becoming effective medicines is a process of elimination. This page explains the process.
-
This section describes how a chemical compound makes the journey from the laboratory to reach the pharmacy shelf as a medicine.